By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Allozyne, Inc. 

1600 Fairview Ave E.
Suite 300
Seattle  Washington  98102  U.S.A.
Phone: 206-518-5700 Fax: 206-518-5799


SEARCH JOBS


Industry
Biotechnology

Segment
Biotechnology





Company News
Allozyne, Inc. Sold For Scrap As MedImmune (AZN) Snaps Up Rights 9/19/2014 6:50:12 AM
Allozyne, Inc. Conducts Round of Employee "Furloughs" 3/15/2013 12:17:09 PM
Poniard Pharmaceuticals, Inc. (PARD) Announces Shareholders Approve Merger With Allozyne, Inc. 11/22/2011 7:39:44 AM
Allozyne, Inc. Announces Positive Results from Phase 1B Trial of AZ01 10/19/2011 7:01:59 AM
Poniard Pharmaceuticals, Inc. (PARD) Announces Effectiveness of Form S-4 Registration Statement for the Proposed Merger with Allozyne, Inc. 10/10/2011 9:16:49 AM
Poniard Pharmaceuticals, Inc. (PARD) Announces Filing of Form S-4 Registration Statement Related to Proposed Merger With Allozyne, Inc. 7/26/2011 9:01:39 AM
Allozyne, Inc. Acquires Poniard Pharmaceuticals, Inc. (PARD), Finds Backdoor Route to NASDAQ 6/23/2011 8:21:49 AM
Allozyne, Inc. Announces Completion of Phase IA Trial by AZ01, a Long Lasting Interferon B for Treatment of Relapsing Remitting Multiple Sclerosis 1/11/2011 9:31:01 AM
Allozyne, Inc. Announces Completion of Phase Ia Trial By Az01, a Long Lasting Interferon ? for Treatment of Relapsing Remitting Multiple Sclerosis 1/10/2011 12:08:00 PM
Allozyne, Inc. Announces Positive Proof of Concept Data For Az17, a Bispecific Th17 Antagonist for Treatment of Autoimmune Diseases 11/16/2010 12:55:50 PM
12
//-->